Organisation paid for research Program year 2025 Source: CMS Open Payments

Optumcare Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$785,551

117 payments

Through program year 2025, Optumcare Clinical Trials LLC is reported as receiving $785,551 in research payments, across 117 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $179,428 8
2023 Research $54,346 8
2022 Research $143,660 38
2021 Research $255,215 50
2020 Research $152,903 13

Breakdown

Who paid Research payments · program years 2020–2025
  1. Pfizer Inc. $444,725 82 payments
  2. Eli Lilly and Company $154,323 2 payments
  3. Merck Sharp & Dohme Corporation $63,187 1 payment
  4. Amgen Inc. $48,122 4 payments
  5. GlaxoSmithKline, LLC. $48,095 9 payments
  6. Teva Pharmaceuticals USA, Inc. $14,330 4 payments
  7. Esperion Therapeutics, Inc. $12,769 15 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3 Randomized Activecontrolled Observerblinded Trial to Assess the Safety Tolerability and Immunogenicity of Menabcwy in Healthy Participants 10 to 26 Years of Age $253,885 38 payments
  2. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $190,840 44 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $89,838 1 payment
  4. A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (Achieve-3) $64,485 1 payment
  5. A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants $63,187 1 payment
  6. A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effec $48,095 9 payments
  7. 20170625_Vesalius - CV $37,347 2 payments
  8. A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma $13,717 2 payments
  9. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $12,769 15 payments
  10. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke $10,775 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record